An Elevated C-reactive Protein Concentration, Prior to Surgery, Predicts Poor Cancer-specific Survival in Patients Undergoing Resection for Gastro-oesophageal Cancer
Overview
Affiliations
There is increasing evidence that the presence of an ongoing systemic inflammatory response is associated with poor outcome in patients undergoing resection for a variety of tumours. The aim of the present study was to examine the relationship between clinico-pathological status, preoperative C-reactive protein concentration and cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. One hundred and twenty patients attending the upper gastrointestinal surgical unit in the Royal Infirmary, Glasgow, who were selected for potentially curative surgery, were included in the study. Laboratory measurements of haemoglobin, white cell, lymphocyte and platelet counts, albumin and C-reactive protein were carried out at the time of diagnosis. All patients underwent en-bloc resection with lymphadenectomy and survived at least 30 days following surgery. On multivariate analysis, only the positive to total lymph node ratio (hazard ratio (HR) 2.02, 95% confidence interval (CI) 1.44-2.84, P<0.001) and preoperative C-reactive protein concentration (HR 3.53, 95% CI 1.88-6.64, P<0.001) were independent predictors of cancer-specific survival. The patient group with no evidence of a preoperative systemic inflammatory response (C-reactive protein < or =10 mg l(-1)) had a median survival of 79 months compared with 19 months in the elevated systemic inflammatory response group (P<0.001). The results of the present study indicate that in patients selected to undergo potentially curative resection for gastro-oesophageal cancer, the presence of an elevated preoperative C-reactive protein concentration is an independent predictor of poor cancer-specific survival.
Min Y, Li X, Chen H, Xu Y, Lan G Pak J Med Sci. 2024; 40(3Part-II):534-543.
PMID: 38356845 PMC: 10862437. DOI: 10.12669/pjms.40.3.8397.
Zhou Q, He Q, He W, Wang C, Liu G, Wang K BMC Cancer. 2023; 23(1):1171.
PMID: 38037003 PMC: 10687783. DOI: 10.1186/s12885-023-11565-z.
Haematological and nutritional prognostic biomarkers for patients receiving CROSS or FLOT.
McNamee N, Nindra U, Shahnam A, Yoon R, Asghari R, Ng W J Gastrointest Oncol. 2023; 14(2):494-503.
PMID: 37201072 PMC: 10186526. DOI: 10.21037/jgo-22-886.
Clinical impact of serum prealbumin in pancreaticobiliary disease.
Park Y, Seo H, Noh B, Kim S, Hong S, Lee N Korean J Clin Oncol. 2023; 18(2):61-65.
PMID: 36945244 PMC: 9942763. DOI: 10.14216/kjco.22008.
Boshier P, Swaray A, Vadhwana B, OSullivan A, Low D, Hanna G Br J Surg. 2022; 109(5):418-425.
PMID: 35233634 PMC: 10364693. DOI: 10.1093/bjs/znac044.